NVS Stock — Price, Charts & Analysis

Novartis AG (NVS) has a trailing P/E of 24.08x and a forward P/E of 16.25x. This places NVS in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

NVS trades with 24.08x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether NVS looks overvalued or undervalued.

NVS's P/E of 24.08x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

NVS's trailing EPS is $6.62 and forward EPS is $9.81. Reported earnings growth is -17.00%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Novartis AG generated for each share. NVS's trailing EPS is $6.62, and investors usually prefer EPS that is positive and growing over time.

Novartis AG has a market cap of $302.97B, making NVS a large-cap stock based on the current market value shown on Worldtickers.

NVS's latest stock price on Worldtickers is $159.40. The latest move is $3.16 or 2.02%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

NVS's quote includes a latest price of $159.40. The market open is $156.17. Previous close is $156.24. The intraday range is $156.11 to $159.72.

NVS is up in the latest quote, with a move of $3.16 or 2.02%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

NVS generated $56.69B in trailing revenue. Revenue growth is 0.80%, which helps show whether demand is expanding or slowing.

NVS's revenue growth is 0.80%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, NVS shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $12.76B.

Gross margin is 74.98%. Margins show how efficiently Novartis AG turns revenue into profit.

Novartis AG carries $49.01B and holds $7.62B in cash.

NVS holds $7.62B on its balance sheet.

NVS's book value per share is $21.86.

Yes, Novartis AG pays a dividend of $4.74 per share annually. The dividend yield is 303.00%. The payout ratio is 71.60%.

NVS's dividend yield is 303.00%. Its payout ratio is 71.60%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for NVS. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Novartis AG's investor relations materials.

NVS's five-year average dividend yield is 351.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 7.27% of NVS shares. Insiders hold 0.01% of shares. Ownership mix helps investors understand how much of Novartis AG is held by professional investors and company insiders.

NVS has 1.9B shares outstanding. Float shares are 1.86B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for NVS, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for NVS is $9.81. Earnings growth is -17.00%. Revenue growth is 0.80%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

NVS's trailing EPS is $6.62. Forward EPS is $9.81. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

NVS is in the Healthcare sector. Its earnings multiple is 24.08x. Its latest displayed growth metric is 0.80%. Compare these figures with sector peers before deciding whether Novartis AG is stronger or weaker than average.

NVS trades at $159.40. The stock trades at 24.08x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Novartis AG's fundamentals.

NVS risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.49, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

NVS should be compared with companies in Drug Manufacturers - General. Its earnings multiple is 24.08x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Novartis AG (NVS) operates in Healthcare, specifically Drug Manufacturers - General. Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revo

NVS trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

NVS stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Novartis AG's official website listed on Worldtickers is www.novartis.com/investors/index.shtml. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Novartis AG employs about 75.27K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Novartis AG is headquartered in Basel, Switzerland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

NVS is in the Healthcare sector and the Drug Manufacturers - General industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

NVS has traded between $121.57 and $170.46 over the past 52 weeks. At $159.40, it is 6.49% below the high and 31.12% above the low. The 52-week range helps gauge long-term price momentum.

NVS is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $154.34 and its 200-day moving average is $146.43.

NVS's RSI is 58.04. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

NVS's latest RSI reading is 58.04, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for NVS is near $149.09. Key resistance is near $160.81. Breaks above resistance or below support can change the short-term technical setup.

NVS's nearest reported support level is $149.09. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

NVS's nearest reported resistance level is $160.81. A breakout above resistance can improve momentum, especially when volume confirms the move.

NVS trades about 1.89M shares daily on average. The latest displayed volume is 756.37K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

NVS's MACD is 0.40, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

NVS is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 58.04 (neutral). MACD is bullish. Nearest support is around $149.09. Resistance is around $160.81. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $155.50 (2.51% from price). MA50 is $154.34 (3.28% from price). MA200 is $146.43 (8.86% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. NVS's MA20 is $155.50. MA50 is $154.34. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

NVS's pivot is near $157.15. Support is near $149.09. Resistance is near $160.81. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for NVS is near $155.75. The next upper resistance zone is near $162.90. These levels help define risk and possible follow-through zones after a breakout or breakdown.

NVS's Bollinger range is roughly $150.00 to $161.01. Band width is near 7.08%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

NVS's ATR-based typical daily range is about 1.98%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 756.37K shares. Average volume is about 1.89M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

NVS's all-time high shown on Worldtickers is $170.46. Its all-time low is $23.24. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

NVS has a beta of 0.49, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.